trazodone has been researched along with MPTP Neurotoxicity Syndrome in 1 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Excerpt | Relevance | Reference |
---|---|---|
"Trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1A and 2A receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis that are encountered in advanced Parkinson's disease (PD)." | 1.48 | Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. ( Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hamadjida, A | 1 |
Nuara, SG | 1 |
Gourdon, JC | 1 |
Huot, P | 1 |
1 other study available for trazodone and MPTP Neurotoxicity Syndrome
Article | Year |
---|---|
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Exce | 2018 |